지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2023.4
- 수록면
- 29 - 36 (8page)
- DOI
- 10.5045/br.2023.2023017
이용수
초록· 키워드
오류제보하기
The prognosis of patients with chronic phase (CP) chronic myeloid leukemia (CML) has significantly improved due to the development of potent BCR::ABL1 tyrosine kinase inhibitors (TKIs). However, approximately 15‒20% of patients ultimately experience treatment failure due to resistance or intolerance to TKI therapy. As the prognosis of patients in whom multiple TKIs fail remains poor, an optimal therapeutic approach is required to treat the condition. Asciminib, an allosteric inhibitor that targets ABL1 myristoyl pocket, has been approved by the Food and Drug Administration for use in patients with CP-CML resistant or intolerant to ≥2 prior TKIs or those with T315I mutation. In a phase 1 trial, asciminib monotherapy showed a relatively favorable safety profile and potent efficacy in patients with and without the T315I mutation. In a subsequent phase 3 trial, asciminib treatment was associated with a significantly higher major molecular response rate and lower discontinuation rate than bosutinib in patients with CP-CML for whom two previous TKIs failed. Several clinical trials are being performed in various clinical settings to evaluate the role of asciminib as a frontline treatment for newly diagnosed CP-CML, either as a single agent or in combination with other TKIs as a second-line or additive treatment to improve treatment-free or deep remission. This review summarizes the incidence, available therapies, and outcomes of patients with CP-CML who experienced treatment failure, the mechanism of action, preclinical and clinical data, and ongoing trials for asciminib.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Tyrosine Kinase Inhibitors in Ph+ Chronic Myeloid Leukemia Therapy: a Review
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Chronic Myeloid Leukemia - Prognostic Value of Mutations
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
An Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians
Korean Journal of Family Medicine
2015 .01
-
Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantation
Blood Research
2023 .04
-
Chronic Myeloid Leukemia With Rare Variant b2a3 (e13a3) BCR-ABL1 Fusion
Annals of Laboratory Medicine
2016 .01
-
Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach
대한암예방학회지
2017 .01
-
Concurrence of e1a2 and e19a2 BCR-ABL1 Fusion Transcripts in a Typical Case of Chronic Myeloid Leukemia
Annals of Laboratory Medicine
2017 .01
-
Chronic myeloid leukemia: a type of MPN
Blood Research
2022 .06
-
Concomitant AID Expression and BCL7A Loss Associates With Accelerated Phase Progression and Imatinib Resistance in Chronic Myeloid Leukemia
Annals of Laboratory Medicine
2017 .01
-
A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities
Blood Research
2021 .12
-
Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia
Blood Research
2023 .04
-
Evaluation of a new flow cytometry based method for detection of BCR-ABL1 fusion protein in chronic myeloid leukemia
Blood Research
2017 .01
-
만성골수성백혈병의 타이로신인산화효소 억제제 치료 중 발생하는 혈관합병증
대한의사협회지
2023 .04
-
Hidden “Preleukemic Phase” of Chronic Myeloid Leukemia Presenting Without Leukocytosis in the Peripheral Blood Unrelated to Chemotherapy in a Patient Diagnosed With Diffuse Large B Cell Lymphoma
Annals of Laboratory Medicine
2017 .01
-
The rs61764370 Functional Variant in the KRAS Oncogene is Associated with Chronic Myeloid Leukemia Risk in Women
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Minor BCR-ABL1-Positive Acute Myeloid Leukemia Associated With the NPM1 Mutation and FLT3 Internal Tandem Duplication
Annals of Laboratory Medicine
2016 .01
-
A case of e1a2 (minor, P190) BCR-ABL1-positive chronic myeloid leukemia in Korea
Blood Research
2021 .12
-
Nilotinib으로 전환 후 호전된 Dasatinib 유발성 단백뇨: 증례 보고
대한내과학회지
2023 .06
-
A Case of Chronic Myeloid Leukemia With Rare Variant ETV6/ABL1 Rearrangement
Annals of Laboratory Medicine
2017 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0